Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Autotaxin (ATX) enzyme hydrolyzes lysophosphatidylcholine to lysophosphatidic acid (LPA).
• Aberrant ATX-LPA signaling is implicated in cancer and fibrosis progression.
• Previous ATX inhibitors targeted non-catalytic sites.

Purpose of the Study:

• Design, synthesize, and evaluate novel steroid-derived ATX inhibitors.
• Investigate a new class of ATX inhibitors targeting the bimetallic catalytic site (Type V).
• Assess the impact of these inhibitors on the ATX-LPA signaling pathway.

Main Methods:

• Chemical synthesis of a focused library of steroid-derived analogues.
• Biochemical assays to evaluate ATX inhibition.
• Phenotypic assays measuring LPA-mediated cellular responses (e.g., signaling cascades, chemotaxis).

Main Results:

• Novel steroid-derived compounds (Type V inhibitors) were synthesized.
• These compounds effectively targeted the ATX bimetallic catalytic site.
• Inhibitors modulated LPA-mediated allostery and reduced LPA1 internalization.
• Downstream signaling cascades and chemotaxis induction were significantly reduced.

Conclusions:

• A unique class of Type V ATX inhibitors was developed.
• These inhibitors demonstrate potent biochemical and phenotypic effects.
• The novel compounds represent a promising therapeutic strategy for targeting the ATX-LPA axis in disease.